Meme İnvaziv Karsinomunda Plektin İzofom 1d’nin Evre-Spesifik Ekspresyon Profili, Prognostik Değeri ve İnvaziv Fenotiple Olan Potansiyel İlişkisi

Öz

Bu çalışma, meme invaziv karsinomunda (BRCA) PLEC geni 1d (PLEC 1d) izoformunun evreye özgü ekspresyon profilini, prognostik önemini ve invaziv fenotiple ilişkisini araştırmayı amaçlamıştır. The database for differentially expressed isoforms and genes in human cancers (Cancer DEIso) veritabanı kullanılarak TCGA verileri üzerinden PLEC 1d’nin evre bazında (I–IV) ekspresyon farklılıkları ve logrank testi ile sağkalım analizleri yapılmıştır. Ayrıca MCF7, MDA-MB-231 ve MCF10A hücre hatlarında PLEC 1d mRNA ifade düzeyleri RT-qPCR ile, total plectin protein düzeyleri ise Western blot ile değerlendirilmiştir. Bulgulara göre, PLEC 1d mRNA ifadesi tüm evrelerde normal dokuya kıyasla anlamlı derecede yüksek bulunmuştur. Sağkalım analizi, evre I (p: 0,712) ve evre IV’te (p: 0,947) anlamlı bir ilişki göstermezken, evre II (p: 0,006) ve evre III’te (p: 0,041) yüksek ekspresyonun daha kötü prognozla ilişkili olduğunu ortaya koymuştur. Bununla birlikte, yüksek metastatik MDA-MB-231 hücre hattında, daha az invaziv MCF7 hücrelerine kıyasla PLEC 1d mRNA ifadesi belirgin şekilde artmıştır (p: 0.001). Total plectin protein düzeyleri, MCF10A’ya göre her iki kanser hücre hattında daha yüksek olup, en yüksek seviye MDA-MB-231’de gözlenmiştir. Sonuç olarak, PLEC 1d ekspresyonu BRCA’da evreye bağımlı prognostik etki göstermekte olup, özellikle evre II ve III’te önemli bir belirteç adayıdır. İnvaziv fenotiple ilişkisi, bu izoformun tümör ilerlemesinde işlevsel rol oynayabileceğini düşündürmektedir. PLEC 1d, metastatik BRCA için potansiyel bir biyobelirteç ve tedavi hedefi olarak değerlendirilmelidir.

Anahtar Kelimeler

• Meme Kanseri
• plectin 1d
• ekspresyon
• metastaz

Destekleyen Kurum

Finansal destek alınmamıştır.

Etik Beyan

Çalışmada yalnızca hücre hatları ve in silico analizler kullanıldığı için etik kurul izni gerekmemektedir.

Stage-Dependent Expression Profile, Prognostic Value and Potential Association with Invasive Phenotype of Plectin Isoform 1d in Breast Invasive Carcinoma

Öz

This study aimed to investigate the stage-specific expression profile, prognostic significance, and association with invasive phenotype of the PLEC gene isoform 1d (PLEC 1d) in breast invasive carcinoma (BRCA). Stage-specific differential expression of PLEC 1d (stages I–IV) and survival analyses using the logrank test were performed on TCGA data via the database for differentially expressed isoforms and genes in human cancers (Cancer DEIso). Additionally, PLEC 1d mRNA expression was assessed by qRT-PCR, and total plectin protein levels were evaluated by Western blot in MCF7, MDA-MB-231, and MCF10A cell lines. The results demonstrated that PLEC 1d expression was significantly elevated in tumor tissues across all stages compared to normal tissue. Survival analysis revealed no significant association in stage I (p: 0.712) or stage IV (p: 0.947); however, higher expression was significantly associated with worse prognosis in stage II (p: 0.006) and stage III (p: 0.041). However, the highly metastatic MDA-MB-231 cell line exhibited significantly higher PLEC 1d mRNA expression levels than the less invasive MCF7 cells (p: 0.001). Total plectin protein levels were higher in both cancer cell lines relative to MCF10A, with the highest levels observed in MDA-MB-231 cells. In conclusion, PLEC 1d expression exerts stage-dependent prognostic effects in BRCA, with significant impact during stages II and III. Its association with an invasive phenotype suggests a functional role in tumor progression. Therefore, PLEC 1d should be considered a potential biomarker and therapeutic target in metastatic BRCA.

Anahtar Kelimeler

• BRCA
• plectin 1d
• expression

Destekleyen Kurum

This study did not receive any financial support.

Etik Beyan

Only commercially available cell lines and in silico analyses were used in this study; consequently, ethical approval was not required.

Kaynakça

1. [1] International Agency for Research on Cancer, “Global Cancer Observatory: Breast cancer fact sheet,” https://gco.iarc.who.int/tomorrow/en/dataviz/tables?years=2050&cancers=20, (Accessed May 2026).
2. [2] Gundesli, H., Kori, M., & Arga, K. Y. (2023). The versatility of plectin in cancer: A pan-cancer analysis on potential diagnostic and prognostic impact of plectin isoforms. OMICS: A Journal of Integrative Biology, 27(6), 281–296. https://doi.org/10.1089/omi.2023.0053.
3. [3] Zhang, T., Haws, P., & Wu, Q. (2004). Multiple variable first exons: A mechanism for cell- and tissue-specific gene regulation. Genome Research, 14, 79–89.
4. [4] Fuchs, P., Zorer, M., Rezniczek, G. A., Spazierer, D., Oehler, S., Castanon, M. J., Hauptmann, R., & Wiche, G. (1999). Unusual 5′ transcript complexity of plectin isoforms: Novel tissue-specific exons modulate actin binding activity. Human Molecular Genetics, 8, 2461–2472.
5. [5] Castanon, M. J., Walko, G., Winter, L., & Wiche, G. (2013). Plectin–intermediate filament partnership in skin, skeletal muscle, and peripheral nerve. Histochemistry and Cell Biology, 140, 33–53.
6. [6] McInroy, L., & Määttä, A. (2011). Plectin regulates invasiveness of SW480 colon carcinoma cells and is targeted to podosome-like adhesions in an isoform-specific manner. Experimental Cell Research, 317(17), 2468–2478. https://doi.org/10.1016/j.yexcr.2011.07.013.
7. [7] Puiffe, M. L., Le Page, C., Filali-Mouhim, A., Zietarska, M., Ouellet, V., Tonin, P. N., et al. (2007). Characterization of ovarian cancer ascites on cell invasion, proliferation, spheroid formation, and gene expression in an in vitro model of epithelial ovarian cancer. Neoplasia, 9(10), 820–829. https://doi.org/10.1593/neo.07472.
8. [8] Katada, K., Tomonaga, T., Satoh, M., Matsushita, K., Tonoike, Y., Kodera, Y., et al. (2012). Plectin promotes migration and invasion of cancer cells and is a novel prognostic marker for head and neck squamous cell carcinoma. Journal of Proteomics, 75(6), 1803–1815. https://doi.org/10.1016/j.jprot.2011.12.018.

9. [9] Shin, S. J., Smith, J. A., Rezniczek, G. A., Pan, S., Chen, R., Brentnall, T. A., et al. (2013). Unexpected gain of function for the scaffolding protein plectin due to mislocalization in pancreatic cancer. Proceedings of the National Academy of Sciences of the United States of America, 110 (48), 19414–19419. https://doi.org/10.1073/pnas.1309720110.
10. [10] Buckup, M., Rice, M. A., Hsu, E. C., Garcia-Marques, F., Liu, S., Aslan, M., et al. (2021). Plectin is a regulator of prostate cancer growth and metastasis. Oncogene, 40(3), 663–676. https://doi.org/10.1038/s41388-020-01557-9.
11. [11] Gao, K., Gao, Z., Xia, M., Li, H., & Di, J. (2023). Role of plectin and its interacting molecules in cancer. Medical Oncology, 40 (10): 280. https://doi.org/10.1007/s12032-023-02132-4.
12. [12] Outla, Z., Oyman-Eyrilmez, G., Korelova, K., Prechova, M., Frick, L., et al. (2024). Plectin-mediated cytoskeletal crosstalk as a target for inhibition of hepatocellular carcinoma growth and metastasis. eLife, 13,RP102205. https://doi.org/10.7554/eLife.102205.2.
13. [13] Zheng, Y., Chen, L., & Wang, H. (2025). PLEC 1a isoform promotes triple-negative breast cancer development. Journal of Experimental & Clinical Cancer Research, 44(1), 25. https://doi.org/10.1186/s13046-024-03295-6.
14. [14] Yang, T. H., Chen, Y. H., Sang, S. C., Lin, P. H., Yang, Y. C., Tsai, K. C., et al. (2021). Cancer DEIso: An integrative analysis platform for investigating differentially expressed gene-level and isoform-level human cancer markers. Computational and Structural Biotechnology Journal, 19, 5149–5159. https://doi.org/10.1016/j.csbj.2021.09.005.
15. [15] Massey Jr., F. J. (1951). The Kolmogorov-Smirnov test for goodness of fit. Journal of the American Statistical Association, *46*(253), 68–78.
16. [16] Boneau, C. A. (1960). The effects of violations of assumptions underlying the t test. Psychological Bulletin, 57 (1), 49–64.
17. [17] Steel, R. G. (1960). A rank sum test for comparing all pairs of treatments. Technometrics, 2 (2), 197–207.
18. [18] Yang, T.-H., & Wu, W.-S. (2013). Inferring functional transcription factor-gene binding pairs by integrating transcription factor binding data with transcription factor knockout data. BMC Systems Biology, 7 (6), 1–14.
19. [19] Yang, T.-H. (2021). An aggregation method to identify the RNA meta-stable secondary structure and its functionally interpretable structure ensemble. IEEE/ACM Transactions on Computational Biology and Bioinformatics, 19(1):75-86. doi: 10.1109/TCBB.2021.3082396.